Today: 8 February 2026
Subscribe
Browse Category

Pharmaceuticals News 3 December 2025 - 8 December 2025

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis (FAP). The news gives investors something they’ve been waiting on for years: early clinical proof that Recursion’s AI‑driven platform might actually work in real patients. GlobeNewswire+1 Shares of Recursion (ticker: RXRX) traded in the mid‑$4 range on Monday, up low single digits intraday after jumping as much as around 6% in pre‑market trading on the back of the data, according to Reuters and Benzinga. Reuters+1 Below
8 December 2025
···
Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

As Wall Street gears up for the opening bell on Monday, December 8, 2025, Merck & Co., Inc. (NYSE: MRK) enters the week at a pivotal moment. The Dow component has rallied hard in recent months, but now faces a mix of powerful growth catalysts and fresh legal and financing questions that could shape the next leg of its move. On Friday, December 5, Merck shares slipped 1.16% to $99.72, marking a second straight daily loss and modest underperformance versus the broader market. The stock is still only about 6% below its 52‑week high of $105.84, set on November 25,
8 December 2025
·
Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

As Wall Street heads into Monday’s session, Eli Lilly and Company (NYSE: LLY) sits at the center of several big storylines: Chinese market access for its Alzheimer’s drug, a fresh FDA decision and new data for cancer therapy Jaypirca, price cuts for blockbuster obesity drug Zepbound, and a wave of institutional positioning. Below is a structured look at what matters for Eli Lilly stock before the U.S. market opens on Monday, December 8, 2025. 1. Where LLY Stock Stands After a Choppy Week In short, LLY heads into Monday as a mega‑cap growth stock that has cooled slightly but still
7 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Updated: December 7, 2025 – For informational purposes only, not investment advice. 1. VRTX stock snapshot as of early December 2025 Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy—and volatile—2025. As of the close on Friday, December 5, 2025, VRTX shares finished around $455.48, giving the company a market value in the $115–117 billion range.Stock Titan+3MacroTrends+3StockInvest+3 Key numbers investors are watching right now: Technically, several short‑term models still classify VRTX as a “buy or hold candidate”: StockInvest.us, for example, highlights a strong short‑term uptrend, with the price up almost 8% over the past two weeks and an estimated 3‑month target
7 December 2025
··
Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt offering, secured fresh regulatory wins in its cardiopulmonary and animal-health franchises, boosted its dividend, and simultaneously ran into a new patent roadblock for its subcutaneous Keytruda injection in Germany. PR Newswire+4Wikipedia+4Stock Titan+4 Against that backdrop, MRK stock is trading near the top of its 52‑week range, and Wall Street is sharpening its forecasts for 2026 and beyond. MRK stock price
7 December 2025
···
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Updated December 7, 2025 – for information only, not investment advice. Novo Nordisk stock today: from market darling to turnaround story Novo Nordisk (NYSE: NVO), the Danish giant behind GLP‑1 blockbusters Wegovy and Ozempic, has gone from Europe’s most valuable listed company to a bruised turnaround story in 2025. For investors, NVO has abruptly shifted from a “can do no wrong” growth icon to a complex mix of structural strengths (dominant GLP‑1 franchise, deep pipeline, global reach) and cyclical headaches (pricing pressure, competition, R&D setbacks). The Alzheimer’s shock: EVOKE and EVOKE+ miss their goal The biggest single blow of 2025
7 December 2025
··
Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly and Company (NYSE: LLY) heads into the final weeks of 2025 as one of the most closely watched stocks on Wall Street – and not just in healthcare. After briefly crossing the $1 trillion market-cap mark in November on the back of explosive demand for its obesity and diabetes drugs, the stock has pulled back slightly but remains near record highs. Reuters+1 As of December 6, 2025, LLY is trading around $1,010 per share, giving it a market value just under the trillion‑dollar level and leaving investors debating whether the latest volatility is a buying opportunity or a
6 December 2025
··
Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Published: December 6, 2025 – For information only, not investment advice. Johnson & Johnson stock (NYSE: JNJ) is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings beats, major acquisitions in neuroscience and oncology, and fresh clinical data in bladder cancer. At the same time, the company is absorbing huge jury verdicts in talc litigation and preparing to spin off its orthopaedics business, setting up a very different J&J for the second half of the decade. Reuters+4Johnson & Johnson Investor Relations+4Johnson & Johnson Investor Relations+4 Below is
6 December 2025
·
Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences stock (NASDAQ: GILD) is trading near the upper end of its 52‑week range as of early December 2025, supported by stronger guidance, big HIV and liver franchises, and a mixed but important year for its oncology pipeline. At the same time, new deals in cell therapy and targeted protein degradation show management leaning into long‑term cancer bets, even at the cost of a bit of near‑term EPS. Here’s a detailed look at the latest price action, earnings, drug news, analyst forecasts and key risks that matter for GILD into 2026. Gilead Sciences stock price and recent trading As
6 December 2025
···
Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Updated: December 5, 2025 Eli Lilly and Company (NYSE: LLY) remains one of the most closely watched stocks in global markets as investors weigh eye‑popping growth in obesity and diabetes drugs against equally eye‑popping valuations and rising political pressure on drug prices. On December 5, 2025, Lilly shares are trading just above the $1,000 mark after recently touching an historic $1 trillion market capitalization, the first time a healthcare company has reached that milestone.CoinCentral At the same time, the company is cutting prices on flagship obesity drug Zepbound, navigating new U.S. “most‑favored‑nation” pricing rules, and preparing to ask regulators for
5 December 2025
··
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK share price today, latest news, dividend, buyback activity and stock forecast as of 5 December 2025. GSK Share Price: Trading Near Multi‑Year Highs After a Strong 2025 GSK plc (LON:GSK; NYSE:GSK) is heading into year‑end 2025 on the front foot. As of the latest close before 5 December 2025, GSK’s London‑listed shares were trading around 1,826–1,837p, while the NYSE‑listed ADR ended at about $48.57 on 4 December.Investing.com+2Shares Magazine+2 That puts the stock close to its 52‑week highs of roughly $48.7 for the ADR and just below recent peaks in London, after a powerful run from roughly $34 per ADR
5 December 2025
··
Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Updated: December 4, 2025 Amgen Inc. (NASDAQ: AMGN) has quietly turned into one of 2025’s standout large‑cap healthcare winners. The biotech heavyweight is trading just below fresh 52‑week highs, powered by a clean sweep of earnings beats, a deepening obesity‑drug story around its MariTide program, and full FDA approval for its lung‑cancer therapy Imdelltra. At the same time, investors are grappling with tax and patent overhangs, looming drug price pressure and an increasingly crowded obesity market. Here’s a deep, Google‑News‑friendly dive into the latest Amgen stock news, forecasts and analysis as of December 4, 2025. Amgen stock today: price, performance
4 December 2025
·
Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Published: December 4, 2025 Key Takeaways Wall Street Re‑rates Regeneron After Big Run — and Bigger Dupixent Story Regeneron Pharmaceuticals has suddenly become one of the most hotly debated large‑cap biotechs on Wall Street. On Thursday, December 4, 2025, multiple analyst moves and fresh data reshaped the Regeneron (REGN) stock narrative: Taken together, these moves signal that, despite a sharp rally off the summer lows, many professionals still see upside in REGN stock, driven primarily by Dupixent, Regeneron’s blockbuster anti‑inflammatory drug co‑developed with Sanofi, and a deepening pipeline in genetics and oncology. Investing.com+1 At the same time, concerns about valuation
4 December 2025
·
Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

As Tonix Pharmaceuticals transitions from clinical-stage hopeful to commercial biotech on the back of its new fibromyalgia drug Tonmya, Wall Street is split between blockbuster dreams and dilution fears. TNXP Stock on December 4, 2025: Price, Volume and Volatility Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) spent Thursday, December 4, 2025 trading around the high‑teens, with several data providers showing the stock near $19–20 per share during U.S. hours. MarketBeat cites a real‑time price of about $19.98, while CoinCodex shows $19.66, both up roughly 10–12% on the day. MarketBeat+1 That price puts Tonix’s market capitalization near $190 million, a tiny cap
4 December 2025
··
Eli Lilly (LLY) Stock Today, 4 December 2025: Zepbound Price Cuts, Jaypirca FDA Win and New $1,200–$1,500 Targets

Eli Lilly (LLY) Stock Today, 4 December 2025: Zepbound Price Cuts, Jaypirca FDA Win and New $1,200–$1,500 Targets

Date: 4 December 2025 Eli Lilly stock at a glance Eli Lilly and Company (NYSE: LLY) is trading around $1,030–$1,040 per share on 4 December 2025, down roughly 1% on the session after slipping from about $1,046 in the previous close. Intraday, the stock has been oscillating roughly between $1,022 and $1,051. Intellectia Over the past year, Lilly shares have traded between $623.78 and $1,111.99, and today’s quote values the company at roughly $975–$980 billion in market capitalization. On recent numbers, that equates to a trailing P/E of about 50.5, a PEG ratio near 1.2 and a beta of ~0.37,
4 December 2025
·
Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

As of December 4, 2025, Bristol Myers Squibb Company (NYSE: BMY) is back on the radar of growth, value and dividend investors. After a sharp rally this week driven by fresh news on its Alzheimer’s drug Cobenfy, an AI-enabled drug discovery milestone and a high‑stakes lawsuit ruling, BMY stock is trading around $50.55, giving the U.S. pharma giant a market capitalization of roughly $104 billion.MarketBeat At the same time, investors are weighing a near‑5% dividend yield, looming patent cliffs for Eliquis and Opdivo, and a newly revived $6.7 billion Celgene CVR lawsuit.Business Wire+2Reuters+2 This article rounds up the latest Bristol
4 December 2025
··
GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK)

GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK)

GSK plc’s share price is pressing against 52‑week highs as 2025 draws to a close, with investors weighing a cluster of near‑term FDA decisions, a major CEO change on 1 January 2026, and a still‑busy share buyback programme. As of 4 December 2025, GSK shares on the London Stock Exchange trade at 1,836.5p, within a day range of 1,827–1,839p and a 52‑week range of 1,242.5–1,848.5p.Investing.com The New York–listed ADR (NYSE:GSK) closed on 3 December at $48.97, just below its 52‑week high of $49.31 and well above its 52‑week low of $31.72.Investing.com That puts GSK stock roughly 50% above its one‑year
4 December 2025
Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson (NYSE: JNJ) is trading around $205–$206 per share on Wednesday, December 3, 2025, just shy of its 52‑week high of about $207.81, after a powerful rally that has lifted the stock roughly 40% this year.MarketBeat+2ChartMill+2 Today’s news flow around JNJ is unusually crowded: Below is a structured look at JNJ stock as of December 3, 2025—covering price action, the day’s key headlines, analyst forecasts through 2027, and the risks that still hang over the story. This article is for information and news purposes only and is not investment advice. JNJ stock today: price, performance and trading backdrop
4 December 2025
·
Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Published: December 3, 2025 Amgen Inc. (NASDAQ: AMGN) is closing out 2025 on a powerful upswing. As of the close on December 3, 2025, Amgen shares finished at $345.42, up about 2% on the day, and nudged higher in after-hours trading.StockAnalysis The move pushed the biotech giant to a fresh 52‑week high near $345.95, extending a year-to-date rally of roughly 35%–37% and a one‑year gain of more than 25%.Investing.com+1 Behind the rally is a cluster of catalysts: strong third‑quarter earnings, a deepening obesity drug story around MariTide, aggressive Phase 3 programs, analyst price‑target hikes, and rising institutional ownership. At the
3 December 2025
··
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Inc. (NYSE: PFE) remains one of the most closely watched healthcare stocks as of December 3, 2025. The share price is still stuck near post‑COVID lows, but a new $10 billion obesity‑drug acquisition, expanding RSV vaccine markets and a hefty dividend yield around 6.5–7% are reshaping the narrative around the stock. Pfizer+2Pfizer+2 Below is a deep dive into where Pfizer stock stands today, which headlines are moving it, and how Wall Street currently values PFE for 2026 and beyond. 1. Pfizer stock today: price, trading range and valuation As of late trading on December 3, 2025, Pfizer shares are
3 December 2025
··
1 … 24 25 26 27 28 … 34

Stock Market Today

AMD stock bounces 8% after brutal midweek slide — what investors watch before Monday

AMD stock bounces 8% after brutal midweek slide — what investors watch before Monday

8 February 2026
AMD shares jumped 8.28% to $208.44 Friday, rebounding after steep losses earlier in the week. Chip stocks rallied as investors bet on continued AI data center spending by major tech firms. Nvidia rose 7.8%, Broadcom gained 7.1%, and the Philadelphia Semiconductor Index closed up 5.7%. Markets now await macroeconomic data and Nvidia’s late-February results.
Intel stock price jumps to $50: China CPU delays and SambaNova funding set up week ahead

Intel stock price jumps to $50: China CPU delays and SambaNova funding set up week ahead

8 February 2026
Intel shares rose 4.9% to $50.59 Friday, tracking a 5.7% jump in the PHLX semiconductor index as investors bet on AI-driven data-center spending. Reuters reported Intel and AMD warned Chinese customers of tighter server CPU supply, pushing Intel’s China prices up over 10%. Intel expects supply to improve in Q2. After the bell, Reuters said Intel plans to invest about $100 million in AI chip startup SambaNova Systems.
Go toTop